<DOC>
	<DOCNO>NCT02475772</DOCNO>
	<brief_summary>Fifteen woman recurrent ovarian cancer treat intraperitoneal chemotherapy cisplatin doxorubicin three escalate dosage schedule . The aim study evaluate safety tolerability doxorubicin cisplatin every 4 week three course use three-group , dose-escalation protocol fix dose-density . The time Frame assessment Primary outcome therefore 12 week . Predefined toxicity criterion apply use CTCAE version 4.0 criterion . The study hypothesis local systemic toxicity increase increase dosage cisplatin doxorubicin three repeat PIPAC course CTCAE grade 4 5 event treatment group .</brief_summary>
	<brief_title>A Study With Intraperitoneal Cisplatin Doxorubicin Recurrent Ovarian Cancer Peritoneal Carcinomatosis</brief_title>
	<detailed_description>This prospective phase I , single-arm ( nonrandomized ) , open-label , three step dose-escalation study cisplatin doxorubicin apply PIPAC 15 patient recurrent ovarian cancer peritoneal cancer . The first 5 patient receive doxorubicin 1.5 mg/m2 body surface 50 ml NaCl 0,9 % cisplatin 7.5 mg/m2 50 ml NaCl 0,9 % q 4 week three course . The next 5 patient receive doxorubicin 2.25 mg/m2 body surface 50 ml NaCl 0,9 % cisplatin 11.25 mg/m2 50 ml NaCl 0,9 % q 4 week three course . The next 5 patient receive doxorubicin 3 mg/m2 body surface 50 ml NaCl 0,9 % cisplatin 15 mg/m2 50 ml NaCl 0,9 % q 4 week three course . This schedule represent three-step , 50 % dose-escalation . Dose density change . The aim study evaluate safety tolerability doxorubicin cisplatin every 4-6 week three course use three-group , dose-escalation protocol fix dose-density . The time Frame assessment Primary outcome therefore 12 week . Predefined toxicity criterion apply use CTCAE version 4.0 criterion , document first , second , third course treatment . Clinical examination include abdominal computed tomography ( CT ) scan first , second , third course treatment , cardiac echocardiography first , second , third course treatment , clinical neurological assessment first , second , third course treatment . Pharmacological study include hematologic , liver , renal function test well cisplatin doxorubicin plasma level blood sample drawn , , 12 h start PIPAC course .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1. clinical and/or radiological evidence PC , 2. age 18 85 year diagnosis recurrent ovarian cancer disease progression least one line previous intravenous chemotherapy platinum compound , 3. blood electrolyte count , liver , renal function parameter within 10 % normal range establish respective laboratory study institution , 4. provision write informed consent , 5. postmenopausal status . 1. extraabdominal metastatic disease , exception isolate pleural carcinomatosis/effusion , 2. chemotherapy surgery within last four week prior first PIPAC application , 3. previous treatment maximum cumulative dos doxorubicin , daunorubicin , epirubicin , idarubicin , and/or anthracyclines anthracenediones , 4. history allergic reaction cisplatin platinum contain compound doxorubicin , 5. severe renal impairment , myelosuppression , severe hepatic impairment , severe myocardial insufficiency , recent myocardial infarction severe cardiac arrhythmia , 6. immunocompromised status immunosuppressive therapy know disease immune system , 7. previous enrolment present study , 8. previous intraabdominal chemotherapy intraabdominal antibody therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>recurrent</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>intraperitoneal</keyword>
	<keyword>cisplatin</keyword>
	<keyword>doxorubicin</keyword>
</DOC>